10.83
+9.95%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sagimet Biosciences
From its filings with the US Securities and Exchange Commission
Sagimet Biosciences is based in Foster City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SGMT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $2.0m.
We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Our second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne.
The critical role of FASN overactivity in MASH makes it an attractive target for drug therapy. Our FASN inhibitor, denifanstat, targets multiple drivers of MASH by reducing steatosis, inflammation and fibrosis.
MASH is an aggressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), a condition where an abnormal buildup of excess fat, known as steatosis, occurs in the liver unrelated to the consumption of alcohol. According to a study published in 2023, MASH is a growing epidemic that affected more than 265 million people worldwide in 2019. It is often associated with insulin resistance, type 2 diabetes, cardiovascular disease, and an increase in overall mortality. Left untreated, damage to the liver can lead to cirrhosis or liver cancer, potentially making liver transplantation necessary. There are few approved treatments for non-cirrhotic MASH (stages F1, F2 and F3 fibrosis) and no approved treatments for cirrhotic MASH (F4).
Quoted from its 10-K, filed 11 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 14 Jul 2023
- Employees
- 16
- Website
- sagimet.com ↗
- Head office
- 950 TOWER LANE, FOSTER CITY, CA, 94404
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. George KembleExecutive Chairman of the Board, since 2011$930,223
- Mr. David HappelPresident, Chief Executive Officer, Director, since 2022$906,164
- Mr. Thierry ChaucheChief Financial Officer$2.4m
- Ms. Elizabeth RozekChief Compliance Officer, General Counsel
- Dr. Eduardo MartinsChief Medical Officer$669,064
- Ms. Elizabeth GrammerIndependent Director$233,532
- Mr. Paul HoelscherIndependent Director$367,693
- Ms. Jennifer JarrettIndependent Director$319,347
- Dr. Anne PhillipsIndependent Director$318,097
- Dr. Beth SeidenbergIndependent Director$228,282
- Mr. Timothy WalbertIndependent Director$365,818
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 27
- Environment
- 30
- Social
- 25
- Governance
- 27
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sagimet Biosciences Inc employs 16 employees in San Mateo, California.
- Denifanstat is a selective FASN inhibitor in development for NASH treatment.
- The company is conducting Phase II trials for acne vulgaris and Phase III for GBM with bevacizumab.
Weaknesses
- The company has only 16 employees, which may limit operational capacity.
- Sagimet Biosciences Inc went public on July 14, 2023, with limited market presence.
- Denifanstat is still in clinical trials without approved treatments yet.
Opportunities
- Denifanstat's development for NASH, acne, and cancer offers multiple therapeutic opportunities.
- The Phase III trial for GBM in combination with bevacizumab could expand treatment options.
- Sagimet Biosciences Inc's focus on FASN inhibitors aligns with metabolic disease research trends.
Threats
- Denifanstat's Phase II and III trials face potential regulatory hurdles in the US market.
- The biotechnology sector has high competition for metabolic disease treatments.
- Sagimet Biosciences Inc's limited employee count may hinder rapid response to market changes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.